Trader consensus for no hantavirus vaccine approval or licensure by the end of 2026 reflects the early development stage of candidates, with most mRNA and DNA platforms still in preclinical animal testing or Phase 1 safety trials as of September 2026. Recent progress includes promising single-dose mRNA results in hamster models against Andes virus and ongoing optimization by groups like Korea University-Moderna and UTMB, yet no Phase 3 efficacy studies are underway for any strain. Hantavirus diversity across regions further complicates broad protection. While an outbreak on the MV Hondius cruise ship heightened visibility and spurred some funding discussions, standard regulatory and manufacturing timelines make 2026 licensure improbable absent an unprecedented acceleration akin to Operation Warp Speed.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · UpdatedHantavirus vaccine in 2026?
Hantavirus vaccine in 2026?
6% chance
$131,791 Vol.
$131,791 Vol.
Dec 31, 2026
6% chance
$131,791 Vol.
$131,791 Vol.
Dec 31, 2026
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus for no hantavirus vaccine approval or licensure by the end of 2026 reflects the early development stage of candidates, with most mRNA and DNA platforms still in preclinical animal testing or Phase 1 safety trials as of September 2026. Recent progress includes promising single-dose mRNA results in hamster models against Andes virus and ongoing optimization by groups like Korea University-Moderna and UTMB, yet no Phase 3 efficacy studies are underway for any strain. Hantavirus diversity across regions further complicates broad protection. While an outbreak on the MV Hondius cruise ship heightened visibility and spurred some funding discussions, standard regulatory and manufacturing timelines make 2026 licensure improbable absent an unprecedented acceleration akin to Operation Warp Speed.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Market Opened: May 4, 2026, 10:39 AM ET
Volume
$131,791End Date
Jan 1, 2027Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.Trader consensus for no hantavirus vaccine approval or licensure by the end of 2026 reflects the early development stage of candidates, with most mRNA and DNA platforms still in preclinical animal testing or Phase 1 safety trials as of September 2026. Recent progress includes promising single-dose mRNA results in hamster models against Andes virus and ongoing optimization by groups like Korea University-Moderna and UTMB, yet no Phase 3 efficacy studies are underway for any strain. Hantavirus diversity across regions further complicates broad protection. While an outbreak on the MV Hondius cruise ship heightened visibility and spurred some funding discussions, standard regulatory and manufacturing timelines make 2026 licensure improbable absent an unprecedented acceleration akin to Operation Warp Speed.
This market will resolve to "Yes" if any vaccine intended for humans and inoculating against Hantavirus (including Hantavirus Pulmonary Syndrome (HPS) or Hemorrhagic Fever with Renal Syndrome (HFRS)) receives full approval from the U.S. Food and Drug Administration between market creation and December 31, 2026, 11:59 PM ET. Otherwise, this market will resolve to "No".
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
The primary resolution source for this market will be official information from the FDA, including its list of approved vaccines (https://www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states), however a consensus of credible reporting may also be used.
Volume
$131,791End Date
Jan 1, 2027Market Opened
May 4, 2026, 10:39 AM ETResolver
0x65070BE91...Trader consensus for no hantavirus vaccine approval or licensure by the end of 2026 reflects the early development stage of candidates, with most mRNA and DNA platforms still in preclinical animal testing or Phase 1 safety trials as of September 2026. Recent progress includes promising single-dose mRNA results in hamster models against Andes virus and ongoing optimization by groups like Korea University-Moderna and UTMB, yet no Phase 3 efficacy studies are underway for any strain. Hantavirus diversity across regions further complicates broad protection. While an outbreak on the MV Hondius cruise ship heightened visibility and spurred some funding discussions, standard regulatory and manufacturing timelines make 2026 licensure improbable absent an unprecedented acceleration akin to Operation Warp Speed.
Experimental AI-generated summary referencing Polymarket data. This is not trading advice and plays no role in how this market resolves. · Updated
Beware of external links.
Beware of external links.
Frequently Asked Questions